Andrew H. Ko

Feb 19, 2024 | inkl.com | Andrew H. Ko

Illustration of neural networks in the human brain. Putting a computer inside someone's brain used to feel like the edge of science fiction. Today, it's a reality. Academic and commercial groups are testing "brain-computer interface" devices to enable people with disabilities to function more independently. Yet Elon Musk's company, Neuralink, has put this technology front and center in debates about safety, ethics and neuroscience. How does a brain chip work?

Feb 14, 2024 | caledonianrecord.com | Andrew H. Ko

By Andrew Ko, Assistant Professor of Neurological Surgery, School of Medicine, University of Washington Putting a computer inside someone's brain used to feel like the edge of science fiction. Today, it's a reality. Academic and commercial groups are testing "brain-computer interface" devices to enable people with disabilities to function more independently. Yet Elon Musk's company, Neuralink, has put this technology front and center in debates about safety, ethics and neuroscience.

Dec 15, 2023 | ascopubs.org | Eileen M. O'Reilly |Andrew H. Ko |Jonathan W. Friedberg

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Dec 15, 2023 | brnw.ch | Eileen M. O'Reilly |Andrew H. Ko |Jonathan W. Friedberg

THE TAKEAWAYThe trial by Burris et al1 is a landmark study not only in the realm of pancreatic cancer but also in the larger field of clinical research.

Aug 17, 2023 | healio.com | Mark Leiser |Mindy Valcarcel |David H. Ilson |Andrew H. Ko

Perspective Back to Top Andrew H. Ko, MD, FASCO Most biliary tract cancer trials include intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer and sometimes ampullary adenocarcinomas. However, each of these entities has its own distinct molecular features.